Parkinson's Disease EGFR Signaling Therapy Companies

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

EGFR (Epidermal Growth Factor Receptor) signaling therapies represent an emerging approach in Parkinson's disease drug development that aims to provide neuroprotection to dopaminergic neurons in the substantia nigra pars compacta. Unlike dopamine replacement therapies that address symptoms, EGFR-targeted approaches seek to protect remaining neurons, support mitochondrial function, enhance autophagy, and potentially modify disease progression.

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

EGFR (Epidermal Growth Factor Receptor) signaling therapies represent an emerging approach in Parkinson's disease drug development that aims to provide neuroprotection to dopaminergic neurons in the substantia nigra pars compacta. Unlike dopamine replacement therapies that address symptoms, EGFR-targeted approaches seek to protect remaining neurons, support mitochondrial function, enhance autophagy, and potentially modify disease progression.

The rationale for EGFR signaling in Parkinson's disease stems from multiple lines of evidence: the receptor is widely expressed in dopaminergic neurons, EGFR activation promotes PI3K/Akt-mediated survival signaling, cross-talk exists with PD-related proteins (LRRK2, alpha-synuclein, GBA), and EGFR supports mitochondrial homeostasis and autophagy["@egfr_mechanism"][@egfr_review].

This category covers companies developing:

• Direct EGFR agonists (EGF peptides, HB-EGF mimetics)
• EGFR kinase modulators (positive allosteric modulators, agonists)
• Growth factor therapies with EGFR activity (HGF/MET, FGF, neurotrophins)
• Indirect EGFR activation (shedding protease inhibitors, ligand delivery)
• Gene therapy approaches (AAV-mediated growth factor expression)
• Cell-based neurotrophin delivery (MSC-based systems)

Market Landscape

The EGFR and growth factor therapy field for Parkinson's disease has evolved from academic research to early commercial programs:

| Era | Focus | Status |
|-----|-------|--------|
| 1990s-2000s | Direct EGF protein infusion | Preclinical/Historic |
| 2010s | AAV gene therapy (GDNF, neurturin) | Clinical (mixed results) |
| 2020s | Small molecule modulators, cell therapy | Active development |

Key Challenges:

• Blood-brain barrier penetration remains the primary obstacle[@egfr_bbb]
• Unlike cancer where EGFR inhibition is desired, PD requires activation
• Oncogenic risk of chronic EGFR activation requires careful monitoring
• Therapeutic window optimization is critical

Key Companies and Programs

Athira Pharma

[Athira Pharma](/companies/athira-pharma) (NASDAQ: ATHA) is a clinical-stage company developing fosgonimeton (ATH-1017), a small molecule that targets the hepatocyte growth factor (HGF) system. While not directly targeting EGFR, the HGF/MET system shares significant overlap with EGFR signaling pathways in the brain and provides neuroprotective effects relevant to PD.

| Attribute | Details |
|-----------|---------|
| Lead Program | Fosgonimeton (ATH-1017) |
| Mechanism | HGF/MET receptor activator |
| Indication | Alzheimer's disease (with relevance to PD) |
| Stage | Phase 2/3 |
| Status | Recruiting |

Relevance to EGFR/PD: The HGF/MET system activates parallel PI3K/Akt and MAPK pathways similar to EGFR, promoting neuronal survival, synaptic function, and neurogenesis. While primarily developed for AD, the neuroprotective mechanisms are applicable to PD.

Mechanism: Fosgonimeton activates MET receptor, which promotes:

• Neuronal survival through PI3K/Akt signaling
• Enhanced synaptic function and plasticity
• Neurogenesis support
• Neuroinflammation modulation
• Cerebral blood flow improvement

SanBio Co., Ltd.

[SanBio Co., Ltd.](/companies/sanbio) (TSE: 4592) is a Japanese regenerative medicine company whose cell therapy platform secretes multiple neurotrophic factors including GDNF, BDNF, NGF, and VEGF. While not exclusively EGFR-targeted, the paracrine secretion profile includes factors that engage EGFR signaling pathways.

| Attribute | Details |
|-----------|---------|
| Lead Product | SB623 (AKUUGO®) |
| Technology | Allogeneic mesenchymal stromal cells |
| Indications | TBI, Stroke (with PD relevance) |
| Stage | Approved (Japan), Phase 2 |
| Headquarters | Tokyo, Japan |

Relevance to EGFR/PD: SB623 cells secrete neurotrophic factors that activate downstream EGFR signaling pathways:

• GDNF supports dopaminergic neuron survival
• BDNF engages TrkB → PI3K/Akt pathways
• VEGF supports neurovascular health
• NGF supports cholinergic and sensory neurons

BrainStorm Cell Therapeutics

[BrainStorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics) (NASDAQ: BCLI) develops the NurOwn® platform, an autologous mesenchymal stromal cell therapy that secretes elevated levels of neurotrophic factors.

| Attribute | Details |
|-----------|---------|
| Lead Platform | NurOwn® |
| Technology | Autologous MSC-NTF cells |
| Indications | ALS (completed Phase 3), MS, PD (research) |
| Stage | Phase 3 completed (ALS) |
| Headquarters | New York, USA |

Relevance to EGFR/PD: NurOwn cells secrete GDNF, BDNF, VEGF, and HGF—all of which engage neuroprotective signaling pathways overlapping with EGFR. The company has conducted research in PD models.

Pipeline:

| Program | Indication | Phase | Status |
|---------|------------|-------|--------|
| NurOwn | ALS | Phase 3 | Completed |
| NurOwn | Progressive MS | Phase 1 | Active |
| NurOwn | Alzheimer's disease | Preclinical | Planning |
| NurOwn | Parkinson's disease | Research | Exploratory |

Trefoil Therapeutics

[Trefoil Therapeutics](/companies/trefoil-therapeutics) is a clinical-stage biotechnology company developing engineered neurotrophic factors with improved pharmacological properties.

| Attribute | Details |
|-----------|---------|
| Headquarters | Boston, Massachusetts |
| Founded | 2021 |
| Focus | Engineered neurotrophic factors |
| Funding | Series B ($55M, 2024) |

Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| TF-201 | Synaptic growth factor | Alzheimer's disease | Phase 1 |
| TF-202 | Neuroprotective factor | Parkinson's disease | Preclinical |

TF-202 for PD: The company's second program specifically targets Parkinson's disease with a neuroprotective factor. While the exact mechanism is proprietary, engineered neurotrophic factors with EGFR-relevant signaling pathways are in development.

Engineering Advantages:

• Improved half-life (extended duration of action)
• Enhanced brain penetration
• Reduced immunogenicity
• Improved stability

Living Cell Technologies

[Living Cell Technologies](/companies/living-cell-technologies) (ASX: LCT) developed NTCELL, an encapsulated cell therapy for Parkinson's disease that provides neurotrophic support through transplanted choroid plexus cells.

| Attribute | Details |
|-----------|---------|
| Product | NTCELL |
| Technology | Encapsulated choroid plexus cells |
| Indication | Parkinson's disease |
| Stage | Phase 1/2a completed |
| Headquarters | Sydney, Australia |

Relevance to EGFR/PD: Choroid plexus cells secrete multiple neurotrophic factors including GDNF and NGF, which engage PI3K/Akt survival pathways similar to EGFR signaling. The encapsulation technology allows sustained, localized delivery.

Clinical Outcomes:

• Phase 1/2a trial demonstrated safety
• Improvements in OFF-medication UPDRS motor scores
• Reduced levodopa-induced dyskinesias in some patients
• Sustained effects observed up to 5 years post-implantation

uniQure

[uniQure](/companies/uniqure) (NASDAQ: QURE) is a gene therapy company with an AAV platform that has explored GDNF delivery for Parkinson's disease.

| Attribute | Details |
|-----------|---------|
| Technology | AAV gene therapy |
| Focus | CNS disorders |
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |

Relevance to EGFR/PD: While primarily focused on GDNF (which engages RET → PI3K/Akt pathways), the company's AAV platform is applicable to growth factor delivery for neuroprotection. EGFR ligand gene therapy (AAV-EGF) represents a potential approach.

Approach: AAV-mediated expression of neurotrophic factors (GDNF, BDNF, or EGF) in the striatum for sustained local delivery to dopaminergic neurons.

Emerging Approaches

Small Molecule EGFR Activators

Drug discovery efforts are identifying brain-penetrant EGFR modulators for neurodegeneration:

| Company/Group | Approach | Stage |
|---------------|----------|-------|
| Academic consortia | BBB-penetrant EGFR agonists | Preclinical |
| Pharma R&D | Positive allosteric modulators | Discovery |
| Biotech startups | Tyrosine kinase agonists | Early development |

Challenges:

• Selectivity for neuronal EGFR
• Avoiding oncogenic signaling
• Optimal dosing for chronic administration
• Biomarker development for patient selection

Gene Therapy Approaches

Viral vector delivery of EGFR ligands represents a promising approach:

| Vector | Ligand | Approach | Stage |
|--------|--------|----------|-------|
| AAV | EGF | Regulated expression | Preclinical |
| AAV | HB-EGF | Cell-type specificity | Research |
| AAV | TGF-α | Dopaminergic targeting | Preclinical |

Advantages:

• Sustained local expression
• Single-dose potential
• Cell-type specific promoters
• Regulated expression systems

Combination Approaches

| Combination | Rationale |
|-------------|-----------|
| EGFR modulators + LRRK2 inhibitors | Complementary neuroprotection |
| Growth factor + alpha-synuclein targeting | Multi-pathway approach |
| Cell therapy + gene therapy | Enhanced trophic support |

Clinical Trial Landscape

| Company | Therapy | Identifier | Phase | Status |
|---------|---------|------------|-------|--------|
| BrainStorm | NurOwn (ALS) | NCT03280056 | Phase 3 | Completed |
| LCT | NTCELL | ACTRN12615000216549 | Phase 1/2a | Completed |
| Various | AAV-GDNF | Various | Phase 1/2 | Various |
| Athira | Fosgonimeton | NCT04861281 | Phase 2/3 | Recruiting |

Research Pipeline Summary

| Approach | Stage | Advantages | Challenges |
|----------|-------|-------------|------------|
| EGF peptide fragments | Preclinical | Direct activation | BBB penetration |
| Small molecule activators | Discovery | Oral bioavailability | Selectivity |
| AAV gene therapy | Preclinical | Sustained delivery | Safety concerns |
| MSC cell therapy | Clinical | Proven safety | Variable function |
| Combination approaches | Preclinical | Multi-target | Complexity |

Related Pathways

• [EGFR Signaling in Parkinson's Disease](/mechanisms/egfr-parkinsons)
• [PI3K/Akt Signaling](/mechanisms/pi3k-akt-signaling)
• [Neurotrophic Signaling](/mechanisms/neurotrophic-signaling-pathway)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GDNF Signaling Pathway](/mechanisms/gdnf-signaling-pathway)
• [Parkinson's Disease Gene Therapy](/companies/pd-gene-therapy-companies)
• [PD Neurotrophin/GDNF Delivery](/companies/pd-neurotrophin-gdnf-delivery)

See Also

• [Alzheimer's Disease Neurotrophin Companies](/companies/ad-neurotrophin-growth-factor-companies)
• [Japanese Neurodegeneration Biotech](/companies/japanese-neurodegeneration-biotech)
• [Israeli Biotech Companies](/companies/israeli-biotech-companies)
• [PD Neurogenesis Companies](/companies/pd-neurogenesis-companies)
• [Cell Therapy for Neurodegeneration](/companies/ad-cell-therapy-companies)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA

Related Analyses:

• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;